Cargando…
Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis
BACKGROUND: Although numerous studies confirmed the marked efficacy of chimeric antigen receptor T cells (CAR-T cells) in many hematologic malignancies, severe cardiovascular toxicities remain to be a major obstacle when incorporating this technology. Furthermore, previous individual investigations...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682079/ https://www.ncbi.nlm.nih.gov/pubmed/36439485 http://dx.doi.org/10.3389/fonc.2022.924208 |
_version_ | 1784834768624418816 |
---|---|
author | Chen, Li-Rong Li, Ya-Jia Zhang, Zheng Wang, Ping Zhou, Tao Qian, Kai Fan, Yu-Xin Guo, Yu He, Gong-Hao Shen, Lei |
author_facet | Chen, Li-Rong Li, Ya-Jia Zhang, Zheng Wang, Ping Zhou, Tao Qian, Kai Fan, Yu-Xin Guo, Yu He, Gong-Hao Shen, Lei |
author_sort | Chen, Li-Rong |
collection | PubMed |
description | BACKGROUND: Although numerous studies confirmed the marked efficacy of chimeric antigen receptor T cells (CAR-T cells) in many hematologic malignancies, severe cardiovascular toxicities remain to be a major obstacle when incorporating this technology. Furthermore, previous individual investigations regarding the cardiovascular toxicities of CAR-T cell therapy also reported controversial conclusions. Therefore, a meta-analysis was performed to further evaluate the impacts of CAR-T cell therapy on cardiovascular toxicities. METHODS: The PubMed, Embase, Web of Science, and ClinicalTrials.gov databases were searched for eligible studies up to April 2022. All analyses were carried out using the R 4.1.0 software. RESULTS: Eventually, 25 related studies consisting of 2,059 patients were enrolled in the current meta-analysis. We discovered that the pooled incidence rate of the all-cause mortality rate was 14.1% and that the pooled incidence rates of overall cardiovascular (CV) events and CV events with cytokine release syndrome (CRS) grade ≥ 2 were 25.6% and 14.2%, respectively. The pooled incidence of hypotension was 28.6%. Further analysis showed that the incidence rates of arrhythmias, cardiovascular dysfunction, heart failure (HF), CV deaths, acute coronary syndrome (ACS), cardiomyopathy, cardiac arrest, and other CV events were 19.2%, 8.0%, 5.3%, 1.8%, 2.5%, 2.9%, 1.3%, and 1.9%, respectively. CONCLUSION: Cancer patients treated with CAR-T cell therapy were at risk for cardiovascular toxicities, of which the most common cardiovascular events were arrhythmias, cardiovascular dysfunction, and heart failure. These findings would contribute to achieving more rational and individualized use of CAR-T cells in clinical treatment. |
format | Online Article Text |
id | pubmed-9682079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96820792022-11-24 Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis Chen, Li-Rong Li, Ya-Jia Zhang, Zheng Wang, Ping Zhou, Tao Qian, Kai Fan, Yu-Xin Guo, Yu He, Gong-Hao Shen, Lei Front Oncol Oncology BACKGROUND: Although numerous studies confirmed the marked efficacy of chimeric antigen receptor T cells (CAR-T cells) in many hematologic malignancies, severe cardiovascular toxicities remain to be a major obstacle when incorporating this technology. Furthermore, previous individual investigations regarding the cardiovascular toxicities of CAR-T cell therapy also reported controversial conclusions. Therefore, a meta-analysis was performed to further evaluate the impacts of CAR-T cell therapy on cardiovascular toxicities. METHODS: The PubMed, Embase, Web of Science, and ClinicalTrials.gov databases were searched for eligible studies up to April 2022. All analyses were carried out using the R 4.1.0 software. RESULTS: Eventually, 25 related studies consisting of 2,059 patients were enrolled in the current meta-analysis. We discovered that the pooled incidence rate of the all-cause mortality rate was 14.1% and that the pooled incidence rates of overall cardiovascular (CV) events and CV events with cytokine release syndrome (CRS) grade ≥ 2 were 25.6% and 14.2%, respectively. The pooled incidence of hypotension was 28.6%. Further analysis showed that the incidence rates of arrhythmias, cardiovascular dysfunction, heart failure (HF), CV deaths, acute coronary syndrome (ACS), cardiomyopathy, cardiac arrest, and other CV events were 19.2%, 8.0%, 5.3%, 1.8%, 2.5%, 2.9%, 1.3%, and 1.9%, respectively. CONCLUSION: Cancer patients treated with CAR-T cell therapy were at risk for cardiovascular toxicities, of which the most common cardiovascular events were arrhythmias, cardiovascular dysfunction, and heart failure. These findings would contribute to achieving more rational and individualized use of CAR-T cells in clinical treatment. Frontiers Media S.A. 2022-11-09 /pmc/articles/PMC9682079/ /pubmed/36439485 http://dx.doi.org/10.3389/fonc.2022.924208 Text en Copyright © 2022 Chen, Li, Zhang, Wang, Zhou, Qian, Fan, Guo, He and Shen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Chen, Li-Rong Li, Ya-Jia Zhang, Zheng Wang, Ping Zhou, Tao Qian, Kai Fan, Yu-Xin Guo, Yu He, Gong-Hao Shen, Lei Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis |
title | Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis |
title_full | Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis |
title_fullStr | Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis |
title_full_unstemmed | Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis |
title_short | Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: A meta-analysis |
title_sort | cardiovascular effects associated with chimeric antigen receptor t cell therapy in cancer patients: a meta-analysis |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682079/ https://www.ncbi.nlm.nih.gov/pubmed/36439485 http://dx.doi.org/10.3389/fonc.2022.924208 |
work_keys_str_mv | AT chenlirong cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT liyajia cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT zhangzheng cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT wangping cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT zhoutao cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT qiankai cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT fanyuxin cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT guoyu cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT hegonghao cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis AT shenlei cardiovasculareffectsassociatedwithchimericantigenreceptortcelltherapyincancerpatientsametaanalysis |